Luai R Zarour, Sudarshan Anand, Kevin G Billingsley, William H Bisson, Andrea Cercek, Michael F Clarke, Lisa M Coussens, Charles E Gast, Cristina B Geltzeiler, Lissi Hansen, Katherine A Kelley, Charles D Lopez, Shushan R Rana, Rebecca Ruhl, V Liana Tsikitis, Gina M Vaccaro, Melissa H Wong, Skye C Mayo
In patients with colorectal cancer (CRC) that metastasizes to the liver, there are several key goals for improving outcomes including early detection, effective prognostic indicators of treatment response, and accurate identification of patients at high risk for recurrence. Although new therapeutic regimens developed over the past decade have increased survival, there is substantial room for improvement in selecting targeted treatment regimens for the patients who will derive the most benefit. Recently, there have been exciting developments in identifying high-risk patient cohorts, refinements in the understanding of systemic vs localized drug delivery to metastatic niches, liquid biomarker development, and dramatic advances in tumor immune therapy, all of which promise new and innovative approaches to tackling the problem of detecting and treating the metastatic spread of CRC to the liver...
March 2017: Cellular and Molecular Gastroenterology and Hepatology